The State of Peptide Vendor Transparency, 2026

Peptide Grades scores research-peptide vendors on five verifiable transparency signals: whether a vendor publishes Certificates of Analysis (COAs), whether those COAs are batch-traceable, whether a vendor names the lab that tested the product, whether it keeps dedicated policy pages, and whether its ownership is identifiable. Affiliate status never moves a grade. This report aggregates those signals across every active vendor we grade, plus 383 observed price points, to describe what the market actually looks like in mid-2026.

The short version: most vendors do something on transparency, but far fewer do the thing that actually lets a buyer verify a product. And price tells its own story. The same molecule can cost many times more per milligram at one vendor than another, with no reliable relationship between a low price and high transparency. The findings below are descriptive, not purchasing advice.

Finding 1: Most vendors grade in the middle

Across 26 active vendors, 7 earn an A, 8 a B, 10 a C, and 1 a D. The market clusters in the middle: a majority of vendors do enough to be credible on some signals while leaving real gaps on others.

Finding 2: Transparency theater, COA access without verifiability

This is the headline gap. 24 of 26 vendors show some COA access: a tab, a sample document, a “COA on request” promise. But only 8 of 26 publish COAs fully and openly, and only 15 of 26 name the lab that ran the test at all. A Certificate of Analysis you cannot match to a batch, from a lab nobody will name, is closer to decoration than evidence.

Finding 3: The same molecule, priced 22.9× apart

We normalized 383 observed price points to a single comparable unit, price per milligram, and measured the spread between the cheapest and priciest listing for each peptide. The dispersion is large and uneven. Tirzepatide, the most-shopped molecule, spans a 22.9× range per milligram across vendors.

The honest caveat matters here: price and transparency are not tightly coupled. A low per-milligram price does not signal a more transparent vendor, and the cheapest listing is frequently not the most transparent one. Buyers cannot use price as a proxy for rigor, and this report does not claim transparency “barely costs more.” The two simply move independently.

Finding 4: Same score, different grade

A surface-level scorecard would treat the five signals as a simple sum. We don't. Editorial review can move a vendor up or down from where the raw number alone would land them, which is why two vendors with an identical signal score can carry different letter grades.

In this dataset, a raw score of 3.5 out of 5 maps to 3 different letter grades (A, B, C). The reason a vendor lands on the better or worse side of the same score is documented in each vendor's grade rationale. For example, a named, accredited lab and batch-matched COAs carry more weight than the raw point total alone suggests, while unverifiable claims pull a vendor down even when boxes are technically ticked.

• Raw score 3.5/5 appears as grades A, B, C across 6 vendors.
• Raw score 3.0/5 appears as grades A, B across 5 vendors.

The takeaway for anyone citing vendor “scores” elsewhere: a number without the evidence behind it can mislead. That is the whole reason we publish the rationale and the underlying signals, not just a grade.

How we measured this

Every figure above is computed at build time from our own first-party data and refreshes as grades and prices change. None of it is hand-entered into this page. Grades come from the five-signal Vendor Transparency methodology, and COA handling specifically follows our COA verification process. Price figures come from the verified price dataset: 383 observations from vendors' own public product pages, normalized to price per milligram.

Caveats and limitations

• Snapshot, not census. This covers the 26 active vendors we currently grade, not every vendor in the market. It is a representative working sample, not an exhaustive registry.
• Disclosure, not assay. We measure whether a vendor discloses COAs, labs, and policies, not whether any individual product is pure. A published COA is a transparency signal, not an independent purity guarantee. Identity and purity claims throughout are directional.
• Observed prices drift. Price points are observed from public product pages on specific dates and change constantly; dispersion ratios describe the spread we saw, not a live quote.
• Price ≠ rigor. Nothing here should be read as “cheaper is worse” or “transparency is free.” Price and transparency move independently in this data.
• Research-use framing. These products are sold for laboratory and research use. This report describes a market; it is not medical advice and not a recommendation to buy or use any substance.